Cargando…

Prehospital tranexamic acid: what is the current evidence?

Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality....

Descripción completa

Detalles Bibliográficos
Autor principal: Napolitano, Lena M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877891/
https://www.ncbi.nlm.nih.gov/pubmed/29766078
http://dx.doi.org/10.1136/tsaco-2016-000056
_version_ 1783310784706641920
author Napolitano, Lena M
author_facet Napolitano, Lena M
author_sort Napolitano, Lena M
collection PubMed
description Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality. But robust evidence regarding the efficacy of prehospital administration of the antifibrinolytic drug TXA on trauma outcomes is lacking. This review examines the current evidence available regarding prehospital TXA efficacy in both military and civilian trauma, and updates available evidence regarding in-hospital TXA efficacy in trauma.
format Online
Article
Text
id pubmed-5877891
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58778912018-05-14 Prehospital tranexamic acid: what is the current evidence? Napolitano, Lena M Trauma Surg Acute Care Open Review Many trauma systems are examining whether to implement prehospital tranexamic acid (TXA) protocols since hemorrhage remains the leading cause of potentially preventable early trauma mortality, and early in-hospital administration of TXA within 3 hours of injury is associated with reduced mortality. But robust evidence regarding the efficacy of prehospital administration of the antifibrinolytic drug TXA on trauma outcomes is lacking. This review examines the current evidence available regarding prehospital TXA efficacy in both military and civilian trauma, and updates available evidence regarding in-hospital TXA efficacy in trauma. BMJ Publishing Group 2017-01-13 /pmc/articles/PMC5877891/ /pubmed/29766078 http://dx.doi.org/10.1136/tsaco-2016-000056 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Napolitano, Lena M
Prehospital tranexamic acid: what is the current evidence?
title Prehospital tranexamic acid: what is the current evidence?
title_full Prehospital tranexamic acid: what is the current evidence?
title_fullStr Prehospital tranexamic acid: what is the current evidence?
title_full_unstemmed Prehospital tranexamic acid: what is the current evidence?
title_short Prehospital tranexamic acid: what is the current evidence?
title_sort prehospital tranexamic acid: what is the current evidence?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877891/
https://www.ncbi.nlm.nih.gov/pubmed/29766078
http://dx.doi.org/10.1136/tsaco-2016-000056
work_keys_str_mv AT napolitanolenam prehospitaltranexamicacidwhatisthecurrentevidence